2. Analysis on Results
In total 98 consecutive liver cirrhotic and transplanted between Mar 2015 and Dec 2017 patients (F 23, M 75, mean age 55 ± 8 years) were enrolled into the study: 30 with HCV (F 11, M 19, mean age 55 ± 7 years), 26 with HCV complicated with HCC (F 6, M 20, mean age 58 ± 5 years) and 42 with ALD (F 6, M 36, mean age 54 ± 8 years). The mean BMI in the study group was 27 ± 4 kg/m2, MELD score 18 ± 9 points and most of patients were class B in CPC. However, in 19 (45%) individuals Child–Pugh class was C (mean 11 points). There were 15 HCV RNA negative patients of 30 (50%) with HCV cirrhosis of the liver at the moment of LT, but only 6 out of 26 (23%) in the group of HCV-HCC individuals.
In total there were 55 individuals (56%) with sarcopenia diagnosed by L3SMI: 44 (59%) men and 11 (48%) females. In the whole study group the mean L3SMI was 47 ± 10 cm2/m2: 41 ± 9 cm2/m2 in females and 49 ± 10 cm2/m2 in men. Patients with alcohol-related liver cirrhosis had the lowest L3SMI when compared to HCV and HCV-HCC subgroups (45 ± 10.3 cm2/m2 vs. 46.7 ± 10 cm2/m2 vs. 50 ± 8.9 cm2/m2; all p < 0.05).
Thirty-three individuals were unable to perform any exercise on the treadmill because of the immobilization and clinical frailty. Majority (67%) of patients unable to perform CPET were sarcopenic.
There was no significant difference between sarcopenic and non-sarcopenic patients in terms of liver failure scores, such as MELD and CPC as well as in the mortality after LT. However, there were substantial differences in MELD scores among subgroups, with the highest values in HCV individuals (23 ± 8.3 points), followed with ALD cirrhotic patients (18.4 ± points) and HCV-HCC transplanted individuals (12.5 ± 6.5 points) (all p < 0.001). Clinical data regarding sarcopenia was summarized in Table 1. Lower L3SMI correlated with lower BMI, lower VO2 peak, higher NTproBNP and correlated with prolonged ICU stay (r = −0.21, p < 0.05). Thus, sarcopenic patients presented reduced cardio-pulmonary performance and were more prone to longer stay at the ICU (Table 2).
Table 1. Comparison between patient with and without sarcopenia, defined by L3SMI.
(n = 55)
(n = 43)
|VO2 Peak (J. eq.)
Table 2. Correlations between sarcopenia, cardiac markers, and clinical variables.
|VO2 Peak (J. eq.)
Moreover, there were substantial differences between patients who performed CPET and individuals unable to perform any exercise in terms of CPC (p < 0.05) and MELD, L3SMI, NTproBNP, as well as prolonged ICU stay (all p < 0.01).
In comparison, in the Kaplan–Meier curves for patients with and without sarcopenia, no significant differences were reported in terms of survival in 90-day post-LT (Figure 1), as well as 1 year (Figure 2) and whole follow-up period (up to 1224 days after surgery) (Figure 3).
Figure 1. Kaplan–Maier curves for survival after liver transplantation in sarcopenic and non-sarcopenic patients in 90 days follow-up. Log-rank Cox (HR 2.46, 95% CI 0.34–17.65, p = 0.420).
Figure 2. Kaplan–Maier curves for survival after liver transplantation in sarcopenic and non-sarcopenic patients in 360 days follow-up. Log-rank Cox (HR 1.05, 95% CI 0.28–3.90, p = 0.943).
Figure 3. Kaplan–Maier curves for survival after liver transplantation in sarcopenic and non-sarcopenic patients in full follow-up period. Log-rank Cox (HR 0.82, 95% CI 0.26–2.56, p = 0.734).
3. Current Insights
It is pointed out that the high number of sarcopenic patients awaiting liver transplantation with correlation between sarcopenia and prolonged ICU stay after LT but not with mortality. More than half of evaluated individuals in analyzed cohort presented sarcopenia. Sarcopenia seemed to be a derivative of alcoholic cirrhosis and more advanced liver disease; both were true for males with end-stage liver disease, suggesting sex differences in this term. In ALD patients both advanced liver disease and alcohol directly contribute to sarcopenia with myosteatosis reaching 68% in sarcopenic patients 
. Alcohol impairs skeletal muscle mitochondrial function and protein synthesis 
, leads to hypogonadism and its effect on muscle 
It inhibits mammalian target of rapamycin complex 1 which role is suppressing autophagy and stimulating protein synthesis 
. Moreover, end-stage liver disease of alcoholic origin was associated with loss of muscle and fat mass as described by Benjamin et al. 
. This alteration in body composition accompanied the progression from compensated to decompensated liver cirrhosis. 
. There was no correlation between sarcopenia and advanced liver impairment in the present study. This finding was in line with data of Kang S.H. et al., who found that MELD was not an independent predictor of mortality in severe sarcopenia in the study with 452 cirrhotic patients 
and pointed out the role of novel MELD-sarcopenia score 
. On the other hand, the additional value of MELD-sarcopenia index in allocation of organ system was questioned by van Vugt et al. 
The universal structured cardiologic protocol applied in liver transplant centers is dedicated mainly for detection of coronary artery disease and its complications. Of note, dobutamine-stress echo is not a standard of cardiac evaluation to LT across the centers. Disadvantages of such strategy is associated with the lack of assessment of heart function during surgery with increased oxygen demand as well as in hemodynamic instability. The novel aspect of presented analysis is the impact of sarcopenia on worse cardio-pulmonary performance, i.e., lower VO2
peak and higher NTproBNP before surgery. These results corroborate previously published data regarding the impact of aerobic capacity on LT prognosis 
. Reduced VO2
peak has been independently associated with 100-day mortality following LT 
. Liver transplant candidates with greater VO2
peak experienced significantly better 12-month survival after surgery 
. Moreover, VO2
at ventilatory threshold was the only predictive factor of mortality after LT 
. A reduction in aerobic power or aerobic endurance correlated with increased mortality 
, and might be a more sensitive predictor of mortality than sarcopenia alone, pointed rather to the muscle function, i.e., chronic immobilization, than mass 
What is more, we also found higher levels of plasma NTproBNP in sarcopenic individuals, supporting the thesis of impaired heart function in terms of reduced muscle mass and strength, as well as mirrored data regarding the reverse impact of higher body mass index on this cardiac biomarker 
. NTproBNP is an independent risk factor of all-cause mortality in patients without heart failure 
. Moreover, newly established cardiac cachexia of multifactorial origin—including endotoxemia, chronic inflammation, long-term neurohormonal overactivation, and upregulation of the transcription the proteolytic ubiquitin–proteasome pathway components—has been described, with only NTproBNP recommended to diagnose this condition as of the date 
Thus, the novel aspect of this analysis is the impact of sarcopenia on worse cardiac performance before surgery with the higher risk of prolonged ICU stay with its further complications after LT in sarcopenic individuals unable to perform any exercise on the treadmill. The population of LT candidates unable to perform an objective CPET should be of interest in planning early recognition, testing and management of sarcopenia and muscle function. As of date, there were no studies analyzing sarcopenia regarding an individual’s cardiopulmonary performance 
In conclusion, the results of the present study are in line with the previously published data linking sarcopenic patients with worse cardiopulmonary assessment result and prolonged ICU stay after LT. The urgent need for early identification and appropriate cardiac testing of sarcopenic LT candidates exists. CPET might be a solution, however only in individuals capable of effort on treadmill. Therefore, there is an unresolved problem with evaluation of immobilized or frailty liver transplant candidates. The population of LT candidates unable to perform an objective CPET should be of interest in planning early recognition, testing, and management of sarcopenia and muscle function.